Round Window Membrane Delivery of l-Methionine Provides Protection from Cisplatin Ototoxicity Without Compromising Chemotherapeutic Efficacy

Li, Geming; Frenz, Dorothy A.; Brahmblatt, Sapna; Feghali, Joseph G.; Ruben, Robert J.; Berggren, Diana; Arezzo, Joseph C.; Water, Thomas R. Van De

doi:10.1016/s0161-813x(00)00010-3

Cited by 91 publications

(85 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many agents have been tested to ameliorate cisplatin-induced ototoxicity including fosfomycin (Schweitzer et al, 1986), sodium thiosulfate (Dickey et al, 2005), d-methionine (Campbell et al, 1996), l-methionine (Li et al, 2001), diethyldithiocarbamate (Rybak et al, 1995), lipoic acid (Rybak et al, 1999), l-Nacetylcysteine , glutathione ester (Campbell et al, 2003), sodium salicylate (Li et al, 2002), ␣-tocopherol (Fetoni et al, 2004), and vitamin E (Teranishi and Nakashima, 2003). Although many agents have been tested in an attempt to prevent cisplatininduced ototoxicity, the US Food and Drug Administration has not approved any drug to date for protection against cisplatin ototoxicity.…”

Section: Discussionmentioning

confidence: 99%

Epicatechin protects the auditory organ by attenuating cisplatin-induced ototoxicity through inhibition of ERK

et al. 2010

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Epicatechin protects the auditory organ by attenuating cisplatin-induced ototoxicity through inhibition of ERK

et al. 2010

View full text Add to dashboard Cite

“…There is also interest in the use of growth factors, antioxidants, apoptosis inhibitors and antisense-oligonucleotides. Animal experiments have shown promising results using locally applied drugs to provide otoprotection from noise and drug toxicity (28,29,30,31,32,33,34,35,36). One extension of such studies is local viral and non-viral gene transfer for the sustained treatment of inner ear disorders (37,38,38,40,41,42).…”

Section: Introductionmentioning

confidence: 99%

Local inner-ear drug delivery and pharmacokinetics

Salt

Plontke

2005

Drug Discovery Today

163

123

View full text Add to dashboard Cite

SummaryA number of drugs are in widespread clinical use for the treatment of inner ear disorders by applying them directly to the inner ear. Many new substances and drug delivery systems specific to the inner ear are under development, and in some cases are undergoing evaluations in animal experiments and in clinical studies. The pharmacokinetics of drugs in the inner ear, however, is not well defined and the field is plagued by technical problems in obtaining pure samples of the inner ear fluids for analysis. Nevertheless, a basic understanding of the mechanisms of drug dispersal in the inner ear has emerged that facilitates the design and interpretation of future pharmacokinetic studies.

show abstract

“…This notion is supported by successful attempts at ameliorating the nephrotoxic or ototoxic side effects in experimental animals in vivo by antioxidant therapy with D-methionine (Campbell et al, 1996(Campbell et al, , 1999Li et al, 2001;Reser et al, 1999), diethyldithiocarbamate acid (Rybak et al, 1995), and sodium thiosulfate (Iwamato et al, 1984;Saito et al, 1997). However, such a pharmacologic intervention administered systemically has frequently been problematic because of detrimental effects on the efficacy of CDDP against certain tumors (Aamdal et al, 1987;Inoue et al, 1991;Li et al, 2001;Reser et al, 1999). Only local delivery of D-methionine to the round window membrane has been shown to protect hearing from CDDP damage without affecting its chemotherapeutic action on the tumor cells (Li et al, 2001).…”

mentioning

confidence: 99%

“…However, such a pharmacologic intervention administered systemically has frequently been problematic because of detrimental effects on the efficacy of CDDP against certain tumors (Aamdal et al, 1987;Inoue et al, 1991;Li et al, 2001;Reser et al, 1999). Only local delivery of D-methionine to the round window membrane has been shown to protect hearing from CDDP damage without affecting its chemotherapeutic action on the tumor cells (Li et al, 2001).…”

mentioning

confidence: 99%

Salicylate Protects Hearing and Kidney Function from Cisplatin Toxicity without Compromising its Oncolytic Action

Sha

Zotova

et al. 2002

Laboratory Investigation

Self Cite

View full text Add to dashboard Cite

SUMMARY:Salicylate has recently been demonstrated to protect against the auditory and vestibular side effects of aminoglycoside antibiotics. Similarities in the toxic mechanisms suggest salicylate as a treatment strategy to prevent the ototoxic side effects of cisplatin (CDDP). We first tested protection of the inner ear in Wistar rats receiving a single infusion of 16 mg CDDP/kg body weight with or without treatment with 100 mg/kg salicylate (bid) for 5 days beginning one day before the CDDP infusion. Cisplatin induced a threshold shift of more than 30 dB (at 14 kHz; measured by auditory evoked brain stem response) that was significantly reduced by salicylate. We then examined the protective potential of salicylate on the cochlea, peripheral nerves, and kidney in a rat model of breast cancer-Fisher344 rats implanted with highly metastatic MTLn3 breast cancer cells. Animals received 3 ϫ 5 mg CDDP/kg (given every third day), and salicylate was administered at 100 mg/kg (bid) from 2 days before to 3 days after CDDP treatment. Salicylate significantly attenuated the CDDP-induced threshold shift from approximately 20 dB (at 16 and 24 kHz) to approximately 5 dB, and drastically reduced the loss of cochlear outer hair cells. Likewise, salicylate protected kidney function (measured as plasma blood urea nitrogen and creatinine levels) from CDDP toxicity. Protection of nerve conduction velocities of both sensory and motor nerves was minimal. The chemotherapeutic efficacy of CDDP on suppression of tumor mass and cancer cell metastasis remained unaffected by salicylate. The results suggest that administration of salicylate may become the basis of an effective therapeutic intervention against the ototoxic and nephrotoxic side effects associated with CDDP chemotherapy. (Lab Invest 2002, 82:585-596).

show abstract

Round Window Membrane Delivery of l-Methionine Provides Protection from Cisplatin Ototoxicity Without Compromising Chemotherapeutic Efficacy

Cited by 91 publications

References 28 publications

Epicatechin protects the auditory organ by attenuating cisplatin-induced ototoxicity through inhibition of ERK

Epicatechin protects the auditory organ by attenuating cisplatin-induced ototoxicity through inhibition of ERK

Local inner-ear drug delivery and pharmacokinetics

Salicylate Protects Hearing and Kidney Function from Cisplatin Toxicity without Compromising its Oncolytic Action

Contact Info

Product

Resources

About